The mutant strains were detected more frequently in treatment-naïve patients than in thosed with previous Peg-IFN-based therapies (23.4% vs 17.7%). Also, the mutant strains were more frequent in women than in men (25.0% vs 15.1%, p<0.05), while were infrequent in patients with Pexidartinib nmr HCC than in those without HCC (10.6% vs 22.5%, p<0.05). Multivariate logistic regression analysis revealed that both sex and serum AFP levels

of patients were independent factors accociating Y93H mutant HCV strains. [Conclusion] A novel assay system to quantify the ratios of Y93H mutant strains among total HVC strains in the sera was established. This system may be useful to determine the indication for NA5A inhibitors in patients with HCV, especially in female patients without HCC in whom Y93H mutant strains were detected in frequent. Disclosures: Satoshi Mochida – Grant/Research Support: Chugai, MSD, Tioray CB-839 nmr Medical, BMS; Speaking and Teaching: MSD, Toray Medical, BMS, Tanabe Mitsubishi The following people have nothing to disclose: Yoshihito Uchida, Junichi Kouyama, Kayoko Naiki Purpose In August 2012, the Centers for Disease Control and Prevention (CDC) called for

all Americans in the “Baby Boomer” generation (born 1945 – 1965) to have one-time screening for hepatitis C (HCV). To assess the impact of the CDC call on screening rates, we compared HCV screening MCE公司 rates between the Baby Boomer and the non-Baby Boomer cohorts in the year before vs. the year after the CDC call to action, and also projected screening rates in the 2nd year following the CDC call. Methods Using data from the nationwide Medivo Lab Exchange Database (Medivo Inc., NY, NY), we analyzed 106,272 practices that screened 5,549,760 adults for HCV between August 2011 and April 2014; 1,523,228 (27.4%) were Baby Boomers and 4,026,532 (72.6%) were non-Baby Boomers. We analyzed rates of HCV screening in the year preceding the CDC call to action (August 2011 – July 2012), in the year following the

CDC call (August 2012 – July 2013), and projected rates in the 2nd year after the CDC call (data from August 2013 – April 2014, projected to July 2014). 2-way ANOVA was utilized to assess the effect of the CDC call to action on HCV screening rates between the 2 groups (Baby Boomers vs. non-Baby Boomers). Results Overall, the average number of patients screened per practice fell in the year following the CDC call (8.14 vs. 7.77; 8.25 projected for the second year following). Turning to the birth cohorts, our analysis shows that in the year following the CDC call to action, there was a 10% increase in the average number of Baby Boomers screened for HCV/practice (4.17 vs. 4.58, p<0.001) and a 10% decrease in the average number of non-Baby Boomers screened/practice (12.11 vs. 10.97, p<0.001).